
 Calliditas Therapeutics AB today announced that the phase 2b TRANSFORM trial met its primary endpoint. The trial showed statistically significant …

Calliditas Therapeutics has announced that the US Food and Drug Administration (FDA) has approved Tarpeyo (budesonide) delayed release capsules to …

The FDA has granted priority review for the New Drug Applicaton (NDA) for Calliditas Therapeutics’ Nefecon, for the treatment of …

